Adi Osovsky, S.J.D.

Dr. Osovsky brings nearly two decades of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. She joins Vor Bio from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. In that role, she led the company’s corporate legal and compliance activities and oversaw information technology. […]

Read More… from Adi Osovsky, S.J.D.

Dallan Murray

Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies. He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with […]

Read More… from Dallan Murray

Qing Zuraw, M.D., M.P.H., M.B.A.

Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was one of the key leaders of […]

Read More… from Qing Zuraw, M.D., M.P.H., M.B.A.

Sandy Mahatme

Mr. Mahatme joins Vor Bio with more than 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, global operations, and shareholder value creation. He most recently served as President, Chief Operating Officer, and Chief Financial Officer of National Resilience, Inc., a biomanufacturing company he […]

Read More… from Sandy Mahatme

Jean-Paul Kress, M.D.

Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi®️ (tafasitamab), and advanced the company’s pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys’ position in oncology innovation […]

Read More… from Jean-Paul Kress, M.D.